Mindray (300760) Q3 2024 earnings summary

Executive summary

• Q1–Q3 revenue reached 29.48 billion RMB, up 8.0% year-over-year, with net profit attributable to shareholders up 8.2% to 10.64 billion RMB.

• Q3 revenue was 8.95 billion RMB, a 1.4% year-over-year increase, while Q3 net profit declined 9.3% year-over-year to 3.08 billion RMB.

• International market revenue grew over 18%, driven by high-end client breakthroughs and new business lines, while domestic growth was under 2% due to delayed procurement and weak demand.

• R&D investment for Q1–Q3 was 2.84 billion RMB, accounting for 9.6% of revenue, with significant product launches in diagnostics, imaging, and life support.

• Achieved NEN 7510-1:2017+A1:2020 certification for information security in the Netherlands and a 2-star+ legality rating in Italy.

Financial highlights

• Q1–Q3 gross margin improved to 64.87%, up 0.71 percentage points year-over-year; Q3 gross margin was 61.69%.

• Net operating cash flow for Q1–Q3 surged 42.5% year-over-year to 11.07 billion RMB.

• Q1–Q3 net margin was 36.08%, with Q3 net margin at 34.36%.

• Basic and diluted EPS for Q1–Q3 were 8.7808 and 8.7776 RMB, up 8.12% year-over-year.

• Total assets at period end were 57.60 billion RMB, up 20.15% from the previous year-end.

Outlook and guidance

• Focus remains on high-end international market penetration and expanding seed businesses, with increased R&D and overseas platform investment to drive long-term growth, while the China market faces short-term pressure.